SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas selection for the U.S. Armys ALATTIS program to develop 10 kV silicon-carbide power devices is driving attention, with traders viewing it as technology validation and a potential opening in defense and infrastructure markets. The reaction is tempered by uncertainty over near-term revenue: the award is a prototype program with undisclosed financial terms, and some traders see the share move as a short-lived pop.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Kodiaks experimental wet-AMD treatments met primary endpoints in the Phase 3 DAYBREAK trial, driving a sharp repricing of the stock. Bulls point to the clinical progress and potential for more durable treatment, while skeptics question its advantage over established therapies and cite pending FDA approval, no product revenue, and financing and pullback risks.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

AstraZenecas multibillion-dollar investment in Summit and clinical collaboration around ivonescimab are driving attention, with traders viewing the deal as a boost to funding and confidence in the cancer drug. The reaction is largely bullish, though some caution it is an equity investmentnot a buyoutand does not settle the drugs FDA outcome; short-squeeze and acquisition talk remains speculative.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

FHFAs decision to let mortgage lenders use VantageScore is fueling concern that competition could weaken FICOs long-standing position and pricing power in mortgage scoring. Traders debate whether the selloff overstates the threat to a still-profitable, entrenched business, while bears also point to valuation and debt-funded buybacks as risks.

Tema ETF Trust - Tema Space Innovators ETF

Tema Space Innovators ETF

NASA is drawing attention as space-sector names rebound and the ETF shows improving chart momentum, with traders noting the sector can rise even while SpaceX (SPCX) lags. Sentiment is mixed: some welcome the broader exposure and add shares, while others blame the funds sizable SPCX position for holding back performance and question managements allocations.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris shares are drawing attention after a sharp run-up that traders associate with apparent large buying and optimism about Recorlev growth and XP-8121s Phase 3 potential. Some speculate about a deal or buyout, but that remains unconfirmed, and others caution that the pipelines commercial timeline is several years away.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Attention centers on Helus Pharmas fully enrolled Phase 3 APPROACH trial of HLP003 for major depressive disorder, with topline results expected in Q4. Traders are positioning around the readout as a high-stakes catalyst, while debating the promise of earlier trial data against clinical uncertainty, possible dilution, and volatility.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

A sharp ZBCN rebound has fueled breakout chatter, with bullish traders pointing to improving chart action while skeptics warn the move may be a short-lived pump. Some also cite Zebecs payroll and payments partnerships as longer-term support, though speculation about additional deals remains unconfirmed.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs AI-data-center connectivity outlook is drawing attention after Fubon initiated coverage with a Buy rating, while traders debate whether the growth case justifies its valuation. The conversation also reflects sharp swings in the shares and broader semiconductor weakness, with bulls focused on AI infrastructure demand and bears warning of further pullbacks.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

An appeals-court ruling that states can regulate Kalshis sports event contracts has renewed attention on the legal fight over prediction markets, with traders viewing restrictions on rivals as a potential advantage for DraftKings regulated sportsbook. The community remains divided over whether DraftKings growing Predictions/DKeX business can offset competition from Kalshi and Polymarket, especially given concerns about customer-acquisition spending and profitability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fidelity Covington Trust - Fidelity MSCI North American Subset Index ETF

Adding risk (buying more)

Trimming/taking profits

Rotating into safer assets

Staying the course, no changes

We&#39;re about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Stocktwits

We're about to enter Q4 - how are you positioning your portfolio for the rest of the year?

Current Price	$25.63
Prev Close	$25.85
Open	$25.65
Dividend Yield	N/A
50-Day Moving Average	$25.55
Beta	N/A
Avg. Volume	836,984.51
PE Ratio	N/A

52-Week High	$26.09
52-Week Low	$24.44
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

FINA Fundamentals